Autopsy report · NCT00706446

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

“Funding was terminated”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 3 months before it stopped.
• 255 participants enrolled.
• Results were posted on the registry 5 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Brigham and Women's Hospital

Sponsor type

University, hospital or other

Conditions

Asthma

Interventions

tiotropium bromide; Salmeterol; Formoterol; Fluticasone propionate; budesonide

Participants

255

Sites

2

Countries

United States

Trials that died the same way

• A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
  “Funding terminated” (97% match in meaning)
• Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis
  “Souces of funding have been terminated” (91% match in meaning)
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
  “Terminated due to loss of funding” (90% match in meaning)
• Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
  “Terminated due to insufficient funding” (90% match in meaning)
• Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
  “Funding terminated by funding source.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.